PEIJIA-B (09996) surged more than 10% in Hong Kong trading, with shares last up 9.07% at HK$4.69, on turnover of HK$4.39 million.

The company announced that its first-half 2026 revenue is expected to be between approximately RMB 415 million and RMB 435 million, representing a year-on-year increase of about 17.4% to 23.1%.

Revenue growth was driven by the continued expansion of the transcatheter valve therapy business, supported by the successful commercialization of new indication products, and sustained growth in the neurointerventional business, fueled by the penetration of self-developed products and strategic partnerships.

During the period, total TAVR implant volumes reached approximately 2,830 units, a significant increase of about 36.5% compared to the same period last year. Hospital coverage expanded to over 850 facilities across Greater China.

The TaurusTrio®, specifically designed for aortic regurgitation (AR), completed commercialization with over 660 implants in mainland China, demonstrating strong market acceptance.